DANSK BIOTEK organizes four major plenary meetings for our members throughout the year to increase our members' knowledge regarding specific biotech topics and to facilitate networking. The events usually take place in February, May, September and November.

We also organize approximately four "saloon" meetings annually. They are small, intimate, "meet the expert" meetings with typically 6-20 participants advocating more in-depth discussion and knowledge-sharing on specific themes.

17 Feb 2021

Almirall and MC2 Therapeutics Enter a License, Collaboration and Commercialization Agreement for European Rights to Wynzora® Cream for Treatment of Plaque Psoriasis

PRESS RELEASE

In this collaboration Almirall will commercialize Wynzora® Cream for treatment of plaque psoriasis in Europe and MC2 Therapeutics will be responsible for manufacturing and supply.

  • MC2 Therapeutics and Almirall partner to make Wynzora® Cream a leading topical product for Plaque Psoriasis in Europe
  • In a large European based Phase 3 clinical trial (n=490), Wynzora® Cream has demonstrated substantial efficacy with a PGA treatment success of 51% and beneficial treatment convenience (1)
  • Marketing Authorization Application (MAA) in Europe of Wynzora® Cream has been filed and approval is expected this year

BARCELONA, Spain and COPENHAGEN, Denmark, February 17, 2021 / B3C newswire / — Almirall S.A. (BME: ALM), a global biopharmaceutical company and MC2 Therapeutics, a commercial stage pharmaceutical company developing a new standard within topical therapies for autoimmune and chronic inflammatory conditions, announced today an agreement under which MC2 Therapeutics has granted Almirall exclusive European rights to commercialize Wynzora® Cream for treatment of plaque psoriasis. In exchange, MC2 Therapeutics is eligible to receive upfront to launch payments of EUR 15 million in addition to significant sales milestone payments and double-digit royalties on the European sales of Wynzora® Cream. Almirall and MC2 Therapeutics partner to make Wynzora® Cream a leading topical product for treatment of plaque psoriasis in Europe – a market, which currently is more than 25 million units in sales volume annually (2). The market represents a significant opportunity for Wynzora® Cream as the calcipotriene and betamethasone dipropionate segment accounts for approximately 35% of share of volume and annual sales of more than $300 million (2).

Read the full press release here

    If you cannot find what you are looking for or if you have feedback to our website, please do not hesitate to contact dd@danskbiotek.dk or +45 5150 0560

    Copyright 2021 Danskbiotek. All rights reserved.